Diversity Supplement: Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
多样性补充剂:引导色氨酸免疫代谢改善肝脏缺血再灌注损伤
基本信息
- 批准号:10632561
- 负责人:
- 金额:$ 3.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAnti-Inflammatory AgentsBiologicalBlood CirculationBlood flowCatalogsCell DeathCellsClinicalDataDiseaseEnzymesFoundationsFutureImmuneImmunocompromised HostInflammationInjectableIschemiaLiverLiver DysfunctionLiver FailureMetabolicMyocardial InfarctionOperative Surgical ProceduresOrganOrgan failurePharmaceutical PreparationsReperfusion InjuryStrokeTechnologyTherapeuticTissuesToxic effectTransplantationTraumaTryptophanTryptophan Metabolism PathwayVascular blood supplybaseclinical practicein vivoinnovationliver ischemianovel therapeuticspreconditioningprogramsside effectsuccesssystemic toxicity
项目摘要
Contact PD/PI: Keselowsky, Benjamin G
Project Summary/Abstract
Many different disease states and surgical interventions result in a period of inadequate
tissue/organ blood supply (i.e., ischemia), that result in reperfusion injury when blood flow is
restored, known as ischemia-reperfusion injury (IRI). IRI causes local inflammation, cell death,
excessive tissue destruction and possible organ failure. Examples are found in transplantation,
trauma, myocardial infarction, stroke, and in particular, IRI is a main cause of liver dysfunction
and failure after liver surgery. Unfortunately, there are currently no therapies available in clinical
practice addressing IRI, where a major problem is the harmful systemic side effects and toxicities
of existing drugs.
To address this problem, we are innovating a new therapeutic technology aiming to program
immune cells toward a metabolic state blocking excessive inflammation by directing tryptophan
metabolism through delivery of an enzyme into circulation. This represents a new class of anti-
inflammatory/immunosuppressive biologic drug, with potential to limit systemic toxicities/side
effects, and with potential to be significantly less immunocompromising. Lack of treatment options
for liver IRI and a catalog of in vivo preliminary data strongly supporting the foundational rationale
of IDO as an innovative new anti-inflammatory agent, make this proposal highly significant.
Looking to the future, success would open opportunity to expand to other anti-inflammatory
applications, for example, pre-conditioning donor grafts for transplantation.
Project Summary/Abstract Page 6
联系PD/PI: Keselowsky, Benjamin G
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin George Keselowsky其他文献
Benjamin George Keselowsky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin George Keselowsky', 18)}}的其他基金
Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
指导色氨酸免疫代谢改善肝脏缺血再灌注损伤
- 批准号:
10595020 - 财政年份:2022
- 资助金额:
$ 3.75万 - 项目类别:
Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
指导色氨酸免疫代谢改善肝脏缺血再灌注损伤
- 批准号:
10444213 - 财政年份:2022
- 资助金额:
$ 3.75万 - 项目类别:
Functionalized Enzyme Treatments for Dual-Targeting of Inflammation in Spinal Cord Injury
功能化酶治疗脊髓损伤炎症的双重靶向
- 批准号:
10284992 - 财政年份:2021
- 资助金额:
$ 3.75万 - 项目类别:
Tissue-Targeted Enzyme for Localized Tryptophan Catabolism to Direct Subcutaneous and Oral Mucosal Inflammatory Responses
用于局部色氨酸分解代谢的组织靶向酶以指导皮下和口腔粘膜炎症反应
- 批准号:
9752509 - 财政年份:2017
- 资助金额:
$ 3.75万 - 项目类别:
Tissue-Targeted Enzyme for Localized Tryptophan Catabolism to Direct Subcutaneous and Oral Mucosal Inflammatory Responses
用于局部色氨酸分解代谢的组织靶向酶以指导皮下和口腔粘膜炎症反应
- 批准号:
9403768 - 财政年份:2017
- 资助金额:
$ 3.75万 - 项目类别:
Biomaterial Delivery System for Type 1 Diabetes Vaccine
1 型糖尿病疫苗的生物材料输送系统
- 批准号:
9285796 - 财政年份:2014
- 资助金额:
$ 3.75万 - 项目类别:
Biomaterial Delivery System for Type 1 Diabetes Vaccine
1 型糖尿病疫苗的生物材料输送系统
- 批准号:
8761784 - 财政年份:2014
- 资助金额:
$ 3.75万 - 项目类别:
Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of In
用于亚细胞靶向递送 In 的树突状细胞靶向微粒
- 批准号:
8707719 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of In
用于亚细胞靶向递送 In 的树突状细胞靶向微粒
- 批准号:
9041572 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of In
用于亚细胞靶向递送 In 的树突状细胞靶向微粒
- 批准号:
8442857 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 3.75万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 3.75万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 3.75万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 3.75万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 3.75万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别: